Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial (Pharmacoepidemiology and Drug Safety, 2024)

(untitled) - Schomaker, M; Denti, P; Bienczak, A; Burger, D; Díaz, I; Gibb, DM; Walker, AS; McIlleron, H